TY - JOUR PY - 2018 DA - 2018// TI - The international classification of headache disorders, 3rd edition JO - Cephalalgia VL - 38 UR - https://doi.org/10.1177/0333102417738202 DO - 10.1177/0333102417738202 ID - ref1 ER - TY - JOUR AU - Steiner, T. J. AU - Stovner, L. J. AU - Vos, T. AU - Jensen, R. AU - Katsarava, Z. PY - 2018 DA - 2018// TI - Migraine is first cause of disability in under 50s: will health politicians now take notice? JO - J Headache Pain VL - 19 UR - https://doi.org/10.1186/s10194-018-0846-2 DO - 10.1186/s10194-018-0846-2 ID - Steiner2018 ER - TY - JOUR AU - Lanteri-Minet, M. PY - 2014 DA - 2014// TI - Economic burden and costs of chronic migraine JO - Curr Pain Headache Rep VL - 18 UR - https://doi.org/10.1007/s11916-013-0385-0 DO - 10.1007/s11916-013-0385-0 ID - Lanteri-Minet2014 ER - TY - JOUR AU - Gooriah, R. AU - Nimeri, R. AU - Ahmed, F. PY - 2015 DA - 2015// TI - Evidence-based treatments for adults with migraine JO - Pain Res Treat VL - 2015 UR - https://doi.org/10.1155/2015/629382 DO - 10.1155/2015/629382 ID - Gooriah2015 ER - TY - JOUR AU - Silberstein, S. D. PY - 2015 DA - 2015// TI - Preventive migraine treatment JO - Continuum (Minneap Minn) VL - 21 UR - https://doi.org/10.1212/CON.0000000000000199 DO - 10.1212/CON.0000000000000199 ID - Silberstein2015 ER - TY - JOUR AU - Deng, H. AU - Li, G. G. AU - Nie, H. AU - Feng, Y. Y. AU - Guo, G. Y. AU - Guo, W. L. AU - Tang, Z. P. PY - 2020 DA - 2020// TI - Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis JO - BMC Neurol VL - 20 UR - https://doi.org/10.1186/s12883-020-01633-3 DO - 10.1186/s12883-020-01633-3 ID - Deng2020 ER - TY - BOOK PY - 2020 DA - 2020// TI - Package insert PB - Amgen Inc. CY - Thousand Oaks ID - ref7 ER - TY - BOOK PY - 2020 DA - 2020// TI - Package insert PB - Lundbeck Seattle BioPharmaceuticals, Inc. CY - Bothell ID - ref8 ER - TY - BOOK PY - 2020 DA - 2020// TI - Package insert PB - Teva Pharmaceuticals USA, Inc. CY - North Wales ID - ref9 ER - TY - BOOK PY - 2019 DA - 2019// TI - Package insert PB - Indianapolis CY - Eli Lilly and Company ID - ref10 ER - TY - JOUR AU - Herd, C. P. AU - Tomlinson, C. L. AU - Rick, C. AU - Scotton, W. J. AU - Edwards, J. AU - Ives, N. AU - Clarke, C. E. AU - Sinclair, A. PY - 2018 DA - 2018// TI - Botulinum toxins for the prevention of migraine in adults JO - Cochrane Database Syst Rev VL - 6 UR - https://doi.org/10.1002/14651858.CD011616.pub2 DO - 10.1002/14651858.CD011616.pub2 ID - Herd2018 ER - TY - JOUR AU - Dodick, D. W. AU - Goadsby, P. J. AU - Silberstein, S. D. AU - Lipton, R. B. AU - Olesen, J. AU - Ashina, M. AU - Wilks, K. AU - Kudrow, D. AU - Kroll, R. AU - Kohrman, B. AU - Bargar, R. AU - Hirman, J. AU - Smith, J. PY - 2014 DA - 2014// TI - Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial JO - Lancet Neurol VL - 13 UR - https://doi.org/10.1016/s1474-4422(14)70209-1 DO - 10.1016/s1474-4422(14)70209-1 ID - Dodick2014 ER - TY - JOUR AU - Dodick, D. W. AU - Lipton, R. B. AU - Silberstein, S. AU - Goadsby, P. J. AU - Biondi, D. AU - Hirman, J. AU - Cady, R. AU - Smith, J. PY - 2019 DA - 2019// TI - Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial JO - Cephalalgia. VL - 39 UR - https://doi.org/10.1177/0333102419858355 DO - 10.1177/0333102419858355 ID - Dodick2019 ER - TY - JOUR AU - Ashina, M. AU - Saper, J. AU - Cady, R. AU - Schaeffler, B. AU - Biondi, D. M. AU - Hirman, J. PY - 2020 DA - 2020// TI - Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1) JO - Cephalalgia. VL - 40 UR - https://doi.org/10.1177/0333102420905132 DO - 10.1177/0333102420905132 ID - Ashina2020 ER - TY - JOUR AU - Lipton, R. B. AU - Goadsby, P. J. AU - Smith, J. AU - Schaeffler, B. A. AU - Biondi, D. M. AU - Hirman, J. AU - Pederson, S. AU - Allan, B. AU - Cady, R. PY - 2020 DA - 2020// TI - Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2 JO - Neurology. VL - 94 UR - https://doi.org/10.1212/WNL.0000000000009169 DO - 10.1212/WNL.0000000000009169 ID - Lipton2020 ER - TY - JOUR AU - Allan, B. AU - Khan, A. AU - Song, Y. AU - Hirman, J. AU - Cady, R. AU - Schaeffler, B. PY - 2019 DA - 2019// TI - PREVAIL: an open-label phase 3 trial to evaluate the safety of eptinezumab administered intravenously in patients with chronic migraine JO - Headache. VL - 59 UR - https://doi.org/10.1111/head.13549 DO - 10.1111/head.13549 ID - Allan2019 ER - TY - JOUR AU - Burch, R. C. AU - Buse, D. C. AU - Lipton, R. B. PY - 2019 DA - 2019// TI - Migraine: epidemiology, burden, and comorbidity JO - Neurol Clin VL - 37 UR - https://doi.org/10.1016/j.ncl.2019.06.001 DO - 10.1016/j.ncl.2019.06.001 ID - Burch2019 ER - TY - JOUR AU - Lipton, R. B. AU - Munjal, S. AU - Alam, A. AU - Buse, D. C. AU - Fanning, K. M. AU - Reed, M. L. AU - Schwedt, T. J. AU - Dodick, D. W. PY - 2018 DA - 2018// TI - Migraine in America symptoms and treatment (MAST) study: baseline study methods, treatment patterns, and gender differences JO - Headache. VL - 58 UR - https://doi.org/10.1111/head.13407 DO - 10.1111/head.13407 ID - Lipton2018 ER - TY - JOUR AU - Dodick, D. W. AU - Ashina, M. AU - Brandes, J. L. AU - Kudrow, D. AU - Lanteri-Minet, M. AU - Osipova, V. AU - Palmer, K. AU - Picard, H. AU - Mikol, D. D. AU - Lenz, R. A. PY - 2018 DA - 2018// TI - ARISE: a phase 3 randomized trial of erenumab for episodic migraine JO - Cephalalgia. VL - 38 UR - https://doi.org/10.1177/0333102418759786 DO - 10.1177/0333102418759786 ID - Dodick2018 ER - TY - JOUR AU - Goadsby, P. J. AU - Reuter, U. AU - Hallstrom, Y. AU - Broessner, G. AU - Bonner, J. H. AU - Zhang, F. PY - 2017 DA - 2017// TI - A controlled trial of erenumab for episodic migraine JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1705848 DO - 10.1056/NEJMoa1705848 ID - Goadsby2017 ER - TY - JOUR AU - Reuter, U. AU - Goadsby, P. J. AU - Lanteri-Minet, M. AU - Wen, S. AU - Hours-Zesiger, P. AU - Ferrari, M. D. AU - Klatt, J. PY - 2018 DA - 2018// TI - Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study JO - Lancet. VL - 392 UR - https://doi.org/10.1016/s0140-6736(18)32534-0 DO - 10.1016/s0140-6736(18)32534-0 ID - Reuter2018 ER - TY - JOUR AU - Detke, H. C. AU - Goadsby, P. J. AU - Wang, S. AU - Friedman, D. I. AU - Selzler, K. J. AU - Aurora, S. K. PY - 2018 DA - 2018// TI - Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study JO - Neurology. VL - 91 UR - https://doi.org/10.1212/wnl.0000000000006640 DO - 10.1212/wnl.0000000000006640 ID - Detke2018 ER - TY - JOUR AU - Skljarevski, V. AU - Matharu, M. AU - Millen, B. A. AU - Ossipov, M. H. AU - Kim, B. K. AU - Yang, J. Y. PY - 2018 DA - 2018// TI - Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial JO - Cephalalgia. VL - 38 UR - https://doi.org/10.1177/0333102418779543 DO - 10.1177/0333102418779543 ID - Skljarevski2018 ER - TY - JOUR AU - Dodick, D. W. AU - Silberstein, S. D. AU - Bigal, M. E. AU - Yeung, P. P. AU - Goadsby, P. J. AU - Blankenbiller, T. AU - Grozinski-Wolff, M. AU - Yang, R. AU - Ma, Y. AU - Aycardi, E. PY - 2018 DA - 2018// TI - Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial JO - JAMA. VL - 319 UR - https://doi.org/10.1001/jama.2018.4853 DO - 10.1001/jama.2018.4853 ID - Dodick2018 ER - TY - STD TI - Pellesi L, De Icco R, Alawie HY, Andersen M, Liang D, Amirguliyev S et al (2020;[Epub ahead of print]) A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. Expert Opin Drug Saf:1–8. https://doi.org/10.1080/14740338.2021.1866537 ID - ref25 ER - TY - JOUR AU - Gklinos, P. AU - Mitsikostas, D. D. PY - 2020 DA - 2020// TI - Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials JO - Ther Adv Neurol Disord VL - 13 UR - https://doi.org/10.1177/1756286420918088 DO - 10.1177/1756286420918088 ID - Gklinos2020 ER - TY - JOUR AU - Abu-Zaid, A. AU - AlBatati, S. K. AU - AlHossan, A. M. AU - AlMatrody, R. A. AU - AlGzi, A. AU - Al-Sharief, R. A. PY - 2020 DA - 2020// TI - Galcanezumab for the management of migraine: a systematic review and meta-analysis of randomized placebo-controlled trials JO - Cureus. VL - 12 UR - https://doi.org/10.7759/cureus.11621 DO - 10.7759/cureus.11621 ID - Abu-Zaid2020 ER - TY - JOUR AU - Kudrow, D. AU - Pascual, J. AU - Winner, P. K. AU - Dodick, D. W. AU - Tepper, S. J. AU - Reuter, U. AU - Hong, F. AU - Klatt, J. AU - Zhang, F. AU - Cheng, S. AU - Picard, H. AU - Eisele, O. AU - Wang, J. AU - Latham, J. N. AU - Mikol, D. D. PY - 2020 DA - 2020// TI - Vascular safety of erenumab for migraine prevention JO - Neurology. VL - 94 UR - https://doi.org/10.1212/wnl.0000000000008743 DO - 10.1212/wnl.0000000000008743 ID - Kudrow2020 ER - TY - JOUR AU - Oakes, T. M. AU - Kovacs, R. AU - Rosen, N. AU - Doty, E. AU - Kemmer, P. AU - Aurora, S. K. AU - Camporeale, A. PY - 2020 DA - 2020// TI - Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies JO - Headache. VL - 60 UR - https://doi.org/10.1111/head.13684 DO - 10.1111/head.13684 ID - Oakes2020 ER - TY - JOUR AU - Nahas, S. J. AU - Kessler, Y. AU - Ning, X. AU - Cohen, J. M. AU - Campos, V. R. AU - Yang, R. PY - 2020 DA - 2020// TI - Cardiovascular safety of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies (4359) JO - Neurology. VL - 94 ID - Nahas2020 ER - TY - JOUR AU - Buse, D. C. AU - Manack, A. AU - Serrano, D. AU - Turkel, C. AU - Lipton, R. B. PY - 2010 DA - 2010// TI - Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers JO - J Neurol Neurosurg Psychiatry VL - 81 UR - https://doi.org/10.1136/jnnp.2009.192492 DO - 10.1136/jnnp.2009.192492 ID - Buse2010 ER - TY - JOUR AU - Ashina, M. AU - Kudrow, D. AU - Reuter, U. AU - Dolezil, D. AU - Silberstein, S. AU - Tepper, S. J. AU - Xue, F. AU - Picard, H. AU - Zhang, F. AU - Wang, A. AU - Zhou, Y. AU - Hong, F. AU - Klatt, J. AU - Mikol, D. D. PY - 2019 DA - 2019// TI - Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions JO - Cephalalgia. VL - 39 UR - https://doi.org/10.1177/0333102419888222 DO - 10.1177/0333102419888222 ID - Ashina2019 ER - TY - JOUR AU - Silberstein, S. D. AU - McAllister, P. AU - Ning, X. AU - Faulhaber, N. AU - Lang, N. AU - Yeung, P. AU - Schiemann, J. AU - Aycardi, E. AU - Cohen, J. M. AU - Janka, L. AU - Yang, R. PY - 2019 DA - 2019// TI - Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of phases 2b and 3 clinical trials JO - Headache. VL - 59 UR - https://doi.org/10.1111/head.13534 DO - 10.1111/head.13534 ID - Silberstein2019 ER - TY - JOUR AU - Bangs, M. E. AU - Kudrow, D. AU - Wang, S. AU - Oakes, T. M. AU - Terwindt, G. M. AU - Magis, D. AU - Yunes-Medina, L. AU - Stauffer, V. L. PY - 2020 DA - 2020// TI - Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies JO - BMC Neurol VL - 20 UR - https://doi.org/10.1186/s12883-020-1609-7 DO - 10.1186/s12883-020-1609-7 ID - Bangs2020 ER - TY - JOUR AU - Zhu, C. AU - Guan, J. AU - Xiao, H. AU - Luo, W. AU - Tong, R. PY - 2019 DA - 2019// TI - Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials JO - Medicine (Baltimore) VL - 98 UR - https://doi.org/10.1097/md.0000000000018483 DO - 10.1097/md.0000000000018483 ID - Zhu2019 ER -